Fundamental Analysis of BENITEC BIOPHARMA INC(NASDAQ:BNTC) stock

Fundamental Rating

BNTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BNTC as it has an excellent financial health rating, but there are worries on the profitability. BNTC does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BNTC has reported negative net income.

In the past year BNTC has reported a negative cash flow from operations.

In the past 5 years BNTC always reported negative net income.

In the past 5 years BNTC always reported negative operating cash flow.

1.2 Ratios

BNTC has a better Return On Assets (-31.23%) than 66.55% of its industry peers.

BNTC's Return On Equity of -33.46% is fine compared to the rest of the industry. BNTC outperforms 76.99% of its industry peers.

		Industry Rank	Sector Rank
ROA	-31.23%
ROE	-33.46%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BNTC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BNTC does not have a ROIC to compare to the WACC, probably because it is not profitable.

BNTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 27.57 indicates that BNTC is not in any danger for bankruptcy at the moment.

BNTC has a better Altman-Z score (27.57) than 95.58% of its industry peers.

There is no outstanding debt for BNTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	27.57

ROIC/WACCN/A

WACC10.87%

2.3 Liquidity

BNTC has a Current Ratio of 15.01. This indicates that BNTC is financially healthy and has no problem in meeting its short term obligations.

BNTC has a better Current ratio (15.01) than 90.09% of its industry peers.

BNTC has a Quick Ratio of 15.01. This indicates that BNTC is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of BNTC (15.01) is better than 90.09% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	15.01
Quick Ratio	15.01

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.09% over the past year.

The Revenue for BNTC has decreased by -100.00% in the past year. This is quite bad

EPS 1Y (TTM)48.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%82.61%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BNTC will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.14% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y62.2%

EPS Next 2Y19.86%

EPS Next 3Y10.14%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNTC. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNTC. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y19.86%

EPS Next 3Y10.14%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BNTC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BENITEC BIOPHARMA INC

NASDAQ:BNTC (1/14/2025, 4:12:23 PM)

After market: 11.14 +0.76 (+7.32%)

10.38

-0.01 (-0.1%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2024-11-14/amc

Earnings (Next)02-11 2025-02-11/bmo

Inst Owners40.22%

Inst Owner Change0%

Ins Owners0.69%

Ins Owner Change0%

Market Cap241.02M

Analysts87.69

Price Target25.94 (149.9%)

Short Float %0.28%

Short Ratio1.04

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-75.31%

Min EPS beat(2)-165.05%

Max EPS beat(2)14.44%

EPS beat(4)1

Avg EPS beat(4)-205.03%

Min EPS beat(4)-563.65%

Max EPS beat(4)14.44%

EPS beat(8)3

Avg EPS beat(8)-161.67%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)5.95%

PT rev (3m)33.83%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-408.46%

EPS NY rev (1m)14.6%

EPS NY rev (3m)-66.3%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	3.76
P/tB	3.76
EV/EBITDA	N/A

EPS(TTM)-6.08

EYN/A

EPS(NY)-4.71

Fwd EYN/A

FCF(TTM)-0.84

FCFYN/A

OCF(TTM)-0.84

OCFYN/A

SpS0

BVpS2.76

TBVpS2.76

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-31.23%
ROE	-33.46%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	15.01
Quick Ratio	15.01
Altman-Z	27.57

F-Score5

WACC10.87%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)48.09%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%82.61%

EPS Next Y62.2%

EPS Next 2Y19.86%

EPS Next 3Y10.14%

EPS Next 5YN/A

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-9.98%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-14.84%

EBIT Next 3Y35.42%

EBIT Next 5YN/A

FCF growth 1Y-24.94%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-23.88%

OCF growth 3YN/A

OCF growth 5YN/A

BENITEC BIOPHARMA INC (BNTC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens